Evidence map›Paper›PMID 28979713›Full record

ArticleWorld journal of gastrointestinal endoscopy2017

Efficacy and safety of liquid nitrogen cryotherapy for treatment of Barrett's esophagus.

Kristen Suchniak-Mussari, Charles E Dye, Matthew T Moyer, Abraham Mathew, Thomas J McGarrity, Eileen M Gagliardi, Jennifer L Maranki, John M Levenick

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastrointestinal endoscopy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Challenges in Endoscopic Therapy of Dysplastic Barrett's Esophagus.Current treatment options in gastroenterology · 2019
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kristen Suchniak-MussariDepartment of Gastroenterology, Allegheny General Hospital, Pittsburgh, PA 15212, United States.
Charles E DyeSection of Gastroenterology and Hepatology, Penn State Hershey Medical Center, Hershey, PA 17033, United States.
Matthew T MoyerSection of Gastroenterology and Hepatology, Penn State Hershey Medical Center, Hershey, PA 17033, United States.
Abraham MathewSection of Gastroenterology and Hepatology, Penn State Hershey Medical Center, Hershey, PA 17033, United States.
Thomas J McGarritySection of Gastroenterology and Hepatology, Penn State Hershey Medical Center, Hershey, PA 17033, United States.
Eileen M GagliardiSection of Gastroenterology and Hepatology, Penn State Hershey Medical Center, Hershey, PA 17033, United States.
Jennifer L MarankiSection of Gastroenterology and Hepatology, Penn State Hershey Medical Center, Hershey, PA 17033, United States.
John M LevenickSection of Gastroenterology and Hepatology, Penn State Hershey Medical Center, Hershey, PA 17033, United States. jlevenick@pennstatehealth.psu.edu.
Creative Research Enterprises (United States) · USAllegheny General Hospital · USPenn State Milton S. Hershey Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the efficacy and safety of liquid nitrogen cryotherapy as a primary or rescue treatment for BE, with and without dysplasia, or intramucosal adenocarcinoma (IMC).

methodsThis was a retrospective, single-center study carried out in a tertiary care center including 45 patients with BE who was treatment-naïve or who had persistent intestinal metaplasia (IM), dysplasia, or IMC despite prior therapy. Barrett's mucosa was resected

resultsFrom 2010 through 2014, 33 patients were studied regarding the efficacy of cryotherapy. Overall, 29 patients (88%) responded to cryotherapy, with 84% having complete regression of all dysplasia and cancer. Complete eradication of cancer and dysplasia was seen in 75% of subjects with IMC; the remaining two subjects did not respond to cryotherapy. Following cryotherapy, 15 patients with high-grade dysplasia (HGD) had 30% complete regression, 50% IM, and 7% low-grade dysplasia (LGD); one subject had persistent HGD. Complete eradication of dysplasia occurred in all 5 patients with LGD. In 5 patients with IM, complete regression occurred in 4, and IM persisted in one. In 136 cryotherapy sessions amongst 45 patients, adverse events included chest pain (1%), stricture (4%), and one gastrointestinal bleed in a patient on dual antiplatelet therapy who had previously undergone EMR.

conclusionCryotherapy is an efficacious and safe treatment modality for Barrett's esophagus with and without dysplasia or intramucosal adenocarcinoma.

Indexed as

Barrett’s esophagusEsophageal adenocarcinomaLiquid nitrogen cryotherapyRadiofrequency ablationTruFreeze

Identifiers

PMID28979713
PMCPMC5605348
OpenAlexW2754955836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.